AR and VR in Healthcare: The 2026 Buyer's Guide to FDA Devices, Vendors, and ROI

Why Fora Soft wrote this playbook

Fora Soft has built real-time video, AI, and immersive software for healthcare and education since 2005. We shipped telehealth and LMS-grade video platforms before the category had a name, delivered HIPAA-scoped video + AI products into clinic and hospital workflows, and built custom AR/VR experiences for training scenarios that no off-the-shelf vendor covered. Companion reading: our AR/VR in Education 2026 buyer’s guide, the longer-form AR and VR in Education playbook, and the Telehealth software buyer’s guide. This article is the decision-oriented companion for healthcare: what the evidence really says, who the vendors are, what a realistic rollout looks like, and when a custom build wins.

Why AR/VR is finally landing in hospitals

Three things changed between 2021 and 2026 that turned AR/VR healthcare from a conference curiosity into a procurement line:

• FDA clearances stacked up. 90+ AR/VR medical devices cleared between 2015 and 2025. Four De Novo pathways opened new categories (RelieVRx, Luminopia, Rejoyn, DaylightRx).
• Reimbursement caught up. HCPCS E1905 (March 2023), Category III CPT 0770T–0774T, Medicare RTM approval for XRHealth. Payers are no longer the blocker they were in 2020.
• Hardware got clinic-ready. Meta Quest 3 for Business at ~$499, Apple Vision Pro in shoulder-arthroscopy pilots, HoloLens 2 driving 3D imaging review. Medical-grade systems now plug into existing PACS.

What this means for budget-holders: AR/VR is no longer a question of “does it work?” It’s a question of “which clinical application, which vendor, at what volume.” A much more answerable question.

The 2026 AR/VR healthcare market in one snapshot

The numbers that frame the buying decision:

• Global AR/VR healthcare market: $5.01–6.41B (2025) → $58.17B (2035), 27.78% CAGR. (Global Growth Insights.)
• Surgical simulation segment: $3.85B (2025) → $15.31B (2035), 14.8% CAGR. Market leader today.
• Mental health therapy: fastest-growing segment — driven by FDA approvals for digital therapeutics (Rejoyn for MDD, DaylightRx for GAD).
• North America: largest regional share, built on early FDA adoption and the reimbursement runway.
• 40% of surgical training projected digital by end of 2026 (industry forecasts) — up from roughly 10% in 2021.
• FDA-cleared AR/VR medical devices: 90+ between 2015 and 2025. Pace accelerating post-2022.
• HCPCS E1905: first CMS national rate for a VR CBT device, effective March 2023 — the inflection point for payer coverage.

What the clinical evidence actually says

The RCT-grade data that matters, 2021–2026:

Chronic lower back pain — RelieVRx (AppliedVR)

• 46% of VR patients achieved ≥50% pain reduction vs. 26% sham control in the pivotal double-blind RCT (n=179).
• Durable at 24 months post-treatment — clinically meaningful reductions in pain intensity, pain interference, sleep disruption, and stress.
• Largest effect sizes in the high-impact chronic pain (HICP) cohort.
• Zero serious adverse events across trials. Format: 6-minute daily home sessions, prescription device.
• FDA De Novo (2021), reaffirmed 2024. Medicare + commercial payer coverage expanding; workers’ compensation partnerships launched 2024.

Amblyopia in children — Luminopia

• 62% best-corrected visual acuity improvement in the amblyopic eye vs. 33% control (Phase 3).
• 88% adherence rate vs. ~50% for traditional eye patching — the game-changer for pediatric compliance.
• 1 hour/day, 6 days/week binocular VR therapy via TV-streamed content.
• FDA De Novo (October 2021). Commercial payer coverage in major plans.

Surgical training — Osso VR, FundamentalVR, PrecisionOS

• Osso VR trainees: 300% higher procedural competence scores vs. traditional-only training in peer-reviewed trials. Fewer instructor prompts required.
• AR surgical training: 90% correct pedicle screw placement vs. 37.5% in control — with a 42% improvement in spatial awareness.
• VR-trained surgeons: 38% faster procedure execution with 45% fewer errors.
• FundamentalVR haptics: sub-millimeter precision, statistically significant error reduction, independently accredited learning platform.

Intraoperative AR navigation — AugMedics xvision

• 97–100% pedicle screw accuracy across multi-study validation.
• 13,000+ patients treated, 71,500+ screws placed across 26 US states — real-world scale, not demo.
• FDA-cleared for spine procedures (C3 to pelvis). Surgeon keeps eye contact with patient while navigation data projects on the retina.

PTSD — VR exposure therapy (VRET)

• 66–90% success rate across VRET protocols in meta-analyses — statistically equivalent to prolonged exposure therapy.
• 3% patient refusal rate for VRET vs. 27% for in-vivo exposure — VR dramatically lowers the engagement barrier.
• Lower re-traumatization risk than imaginal exposure; therapist retains full control of intensity and pacing.
• Demonstrated in veteran populations and first-responder cohorts (ambulance crews, firefighters).

Labor pain, burn pain, stroke rehab — the breadth

• Labor pain: 77% of patients report VR reduced pain, 95% would use again, 82% very high satisfaction. No adverse maternal or fetal effects.
• Pediatric burn dressing changes: moderate-to-large effect sizes for pain reduction, exceeding traditional distraction and comparable to opioid analgesia — without respiratory risk.
• Stroke rehab: measurable improvement in upper-limb function, balance, and gait; benefit plateaus after >20 hours of VR therapy; <8% mild cybersickness.
• Anatomy education: 42% improvement in 3D spatial reasoning; 95–98% student satisfaction with VR vs. traditional and cadaveric methods.

Where AR/VR actually works — 10 clinical applications with evidence

1. Surgical training and competence

Risk-free procedural repetition with instrumented performance metrics. Osso VR (300% competence gains), FundamentalVR (haptic precision), PrecisionOS (orthopedic), Surgical Theater (neurosurgery), Virtual Incision + NVIDIA Isaac (robotic-assisted). Specialties covered: orthopedic, neurosurgery, general, cardiac, robotic. Typical payback: 12–24 months on a 40-surgeon annual cohort.

2. Preoperative planning and patient-specific simulation

3D reconstruction from CT/MRI lets surgeons rehearse approach, trajectory, and implant sizing before entering the OR. ImmersiveTouch (ImmersiveView Surgical Plan) and Surgical Theater (Precision VR) are the leaders — Surgical Theater has served 1,100+ Stanford neurosurgery patients through the care continuum. Secondary benefit: informed consent conversations that patients actually understand.

3. Intraoperative AR guidance

Real-time overlay of patient anatomy, navigation data, and the surgical plan on the OR field. AugMedics xvision leads in spine (97–100% accuracy, 13K+ patients). Broader telementoring via Proximie. The 2026 direction: AR as an “intelligent OR co-pilot” augmenting, not replacing, the surgeon.

4. Chronic pain management (behavioral)

FDA-approved digital therapeutics replacing opioid-first protocols for eligible patients. RelieVRx for CLBP is the anchor product (46% vs. 26% sham). Other target conditions studied: CRPS, fibromyalgia, cancer pain, post-op pain, phantom limb pain. Mechanism: immersive distraction + CBT + body awareness + relaxation training, 6 minutes daily at home.

5. Mental health exposure and CBT

VRET for PTSD, phobias, OCD, anxiety. oVRcome (phobias, social anxiety), PsyTech VR (multi-condition), BehaVR (addiction + mental health). Advantage over in-vivo exposure: 3% refusal vs. 27%, therapist-controlled dose, safer scenarios (combat triggers, contamination OCD). FDA-approved emerging products: Rejoyn (MDD), DaylightRx (GAD).

6. Neurorehabilitation

Post-stroke, TBI, Parkinson’s, spinal-cord injury. MindMotion GO (MindMaze): FDA 510(k)-cleared home-based motor rehab, plugs into TV. XRHealth (XR CareCart): plug-and-play station for PT/OT/mental-health remote therapy with Medicare RTM reimbursement. Evidence: upper-limb function, balance, gait all measurably improve; >20 hours dose-response threshold.

7. Pain management in acute settings

Labor pain (77% patient-reported reduction), pediatric burn dressing changes (moderate-to-large effect), procedural pain (wound care, IV starts). CPT 0770T–0774T (Category III) cover virtual reality procedural dissociation. Smartphone-based VR viable for budget-constrained settings.

8. Amblyopia and pediatric vision therapy

Luminopia (FDA De Novo) turns the adherence problem into the solution — 88% compliance vs. ~50% for traditional patching. Binocular VR therapy via TV-streamed content; 1 hour/day, 6 days/week.

9. Medical student and resident anatomy education

Interactive 3D structures, manipulable and annotated, replacing or augmenting cadaveric dissection. Outcomes: 42% improvement in 3D spatial reasoning; 95–98% student satisfaction. HoloLens 2 drives point-of-care 3D MRI visualization in teaching hospitals.

10. Telepresence and remote specialty guidance

Remote expert telementoring, virtual consult rooms, remote therapy monitoring. Proximie (OR telepresence + training library), XRHealth (clinician–patient VR telehealth), MyndVR / Rendever (senior-living engagement and memory care). 5G + XR is the 2026–2027 combined bet.

The 2026 vendor landscape — who to evaluate

The short list of vendors serious enough to be on a shortlist. Vet the ones that match your clinical problem — not all of them.

The 2026 medical headset landscape

The hardware question is largely solved for most clinical scenarios. What to buy, and what each trade-off earns you:

Meta Quest 3 for Business — the default clinical / training headset

Mature ecosystem, strong pass-through video, MDM-supported, plays with Osso VR, FundamentalVR, Virti, XRHealth, AppliedVR’s home-use devices. Pick this for training programs and home-based therapy at scale.

Apple Vision Pro — the premium surgical-planning pick

Superior display, camera resolution (handles bright OR lighting better than most competitors), hand-eye tracking. Active pilots in shoulder arthroscopy, neuronavigation prototypes. $3,499, with increased cognitive load in time-sensitive procedures a live concern. Pick this for non-time-critical planning, premium education, patient consent visualizations.

Microsoft HoloLens 2 — the established AR clinical workhorse

Point-of-care 3D MRI visualization, pre-surgical anatomy review, mature integrations with healthcare imaging. Pick this where AR (not VR) is the answer, and where HoloLens already has a clinical integration.

Magic Leap 2 — emerging clinical AR

Growing partnerships in surgical guidance and medical visualization. Pick this when a specific medical-imaging or surgical-guidance partnership has been validated on the platform.

Varjo XR-4 — professional high-fidelity XR

Best-in-class resolution for precision imaging and surgical planning. Enterprise price point. Pick this for research settings, advanced surgical planning, or diagnostics where fidelity drives the decision.

What a real clinical deployment costs, Year 1

Three representative scenarios, conservative 2026 budgets:

Scenario A — surgical training program (20 surgeons, 1 specialty)

Context: a single surgical OR hour in the US runs $1,500–$4,000 all-in. If VR training reduces OR revisions, revision surgeries, or instructor dependency by even a small margin across 20 surgeons, the program pays for itself inside 18 months.

Scenario B — chronic pain digital therapeutic (500 patients/year)

RelieVRx prescription devices at per-patient licensing (commercial payer, workers’ comp, or DME pathway). Typical program economics: $800–$1,500 per patient all-in, with reimbursement coverage expanding. Cost baseline: injection-based chronic pain management and opioid management run $3,000–$10,000/patient/year. Digital therapeutic is economically compelling below $2,000/patient when clinical outcomes hold.

Scenario C — VR rehabilitation clinic (PT/OT + neurorehab)

XR CareCart deployment (1 station) + XRHealth platform subscription + Medicare RTM billing. Typical Year 1: $15,000–$30,000 hardware/software; reimbursement via RTM codes (99453, 99457, 99470) plus standard PT/OT codes. Margin depends on patient volume; break-even typically 100–150 patient-visits/year per station.

Buy off the shelf, or build custom? The honest rule

Off-the-shelf platforms cover most high-volume clinical applications. Custom wins when what you need doesn’t exist — or when vendor economics don’t pencil out for your volume.

Buy off-the-shelf when

• Your clinical application maps to an existing FDA-cleared device (CLBP → RelieVRx, amblyopia → Luminopia, post-stroke → MindMotion GO).
• Your training specialty is well-covered by existing platforms (Osso VR, PrecisionOS, FundamentalVR, Surgical Theater).
• You need a faster path to clinical pilot (weeks, not months).
• Reimbursement visibility matters — FDA clearance + established CPT coding path is the trust signal for payers.
• Your volume is under 500 patients/year or 40 trainees/year — the fixed cost of custom build rarely amortizes below that.

Build custom when

• The device, medication, or protocol is proprietary (vendor-specific surgical instrument, a pharmaceutical company’s adherence-training scenario, a device manufacturer’s rep training).
• EHR / PACS / DICOM integration matters and off-the-shelf doesn’t deliver it natively.
• HIPAA + on-prem deployment is required and vendor SaaS won’t fly with your compliance team.
• You have 500+ patients or trainees annually to amortize development across.
• You need custom analytics, outcome instrumentation, or direct integration with outcome registries.
• You’re pursuing FDA clearance (510(k), De Novo, or SaMD) and need design-control ownership over the software.

What a custom clinical AR/VR build actually costs

Clean scope, clinician + SME engagement, HIPAA-aware architecture, Unity or Unreal on Quest 3 + Vision Pro + WebXR:

• MVP (single scenario, no FDA track): $60K–$150K, 10–16 weeks.
• Production-grade (multi-scenario, LMS/EHR integration, analytics): $180K–$400K, 4–8 months.
• FDA-track SaMD (510(k) or De Novo submission, design controls, clinical validation support): $500K–$1.5M+, 12–24 months, plus regulatory consulting.
• Agent Engineering (our AI-assisted delivery) compresses routine 3D, interaction logic, and integration work by 25–40% — the savings usually fund the design-control + clinical work that actually moves the FDA needle.

FDA pathways, SaMD, and what regulators actually ask for

Most AR/VR medical products hit one of four pathways. Pick the wrong one and you lose 6–12 months.

510(k) — the predicate route

Used for surgical simulators and navigation devices with an existing substantially-equivalent predicate. 3–6 month timeline when done well. Most AR surgical guidance devices (beyond the pioneers) use this. Lower clinical evidence bar, but still requires design controls and validation.

De Novo — for first-of-kind digital therapeutics

Required when no predicate exists. RelieVRx, Luminopia, Rejoyn, DaylightRx all came through here. 6–12 month timeline. Creates a new device classification and special controls (benefit for later entrants). Clinical evidence bar is high: RCT vs. sham control is typical for therapeutic claims.

Software as a Medical Device (SaMD)

The FDA framework covering software-based interventions. Risk-based classification drives 510(k) vs. De Novo route. Critical considerations: level of risk to patient on software failure, validation in intended use environment, cybersecurity, software lifecycle management. IEC 62304 is the governing development standard.

Breakthrough Device Designation

Expedited review for devices addressing unmet clinical need. Several VR pain and PTSD devices have used this route. Benefits: priority review, interactive FDA feedback, faster commercial access.

Reimbursement in 2026 — coding, coverage, and where it’s actually working

Reimbursement is finally a real story, not a pitch deck:

The codes that matter

• HCPCS E1905 (effective March 2023): VR CBT device with pre-programmed therapy software. CMS-set national rate. First national reimbursement code for a VR digital therapeutic.
• CPT 0770T: VR-augmented behavioral health service (Category III add-on). Requires base behavioral health code; variable commercial coverage.
• CPT 0771T–0774T: Virtual reality procedural dissociation (VRPD) for acute pain. Category III; variable coverage.
• Remote therapy monitoring (99453, 99457, 99470): used by XRHealth after earning Medicare approval for VR-delivered PT/OT monitoring.
• Behavioral health codes (90834, 90837): base codes under which VR-augmented sessions get billed.

Where payers are actually paying

• Medicare: E1905 reimbursed; XRHealth RTM approved.
• Commercial payers: expanding coverage for RelieVRx under DME pathway; Luminopia covered in major commercial plans; variable by state and plan.
• Workers’ compensation: AppliedVR partnership launches in 2024 delivered the first systematic workers’-comp pathway for VR CLBP therapy.
• Value-based / outcomes-based contracting: emerging for behavioral health digital therapeutics. Pay-for-response models.

Barriers to watch

Prior authorization burden is high for novel therapies. Many Category III codes lack CMS national rates. Commercial plan-to-plan variance is real. Anything below FDA clearance is a tough reimbursement sell — wellness/pilot categories rarely get covered. The good news: HCPCS E1905 set the precedent, and CMS is signaling openness to more digital therapeutic codes in 2026–2027.

HIPAA, cybersecurity, and the compliance scope you cannot skip

Three realities every clinical AR/VR deployment runs into:

HIPAA in multiplayer VR

Shared immersive environments with multiple patients are inherently risky — voice, visual, and biometric data are all PHI. Solutions: per-patient isolated virtual spaces, encrypted audio channels, documented access controls, Business Associate Agreements (BAAs) with every vendor touching PHI.

Biometric + motion data as PHI

Motion tracking, eye gaze, heart rate, and performance analytics collected during clinical VR sessions are all PHI if tied to an identified patient. That means encryption at rest and in transit, authenticated access, audit logs, and incident response protocols under the HIPAA Security Rule.

Cybersecurity baseline

FDA Premarket Cybersecurity Guidance (2022) + NIST Cybersecurity Framework + IEC 62304 medical device software standards. Required controls: end-to-end encryption, MFA for clinicians, network segmentation, intrusion detection, penetration testing, documented patch management, SBOM (software bill of materials) disclosure.

The real implementation challenges — and how to beat them

Cybersickness

5–10% of patients experience nausea or dizziness, elevated in vestibular-impaired populations (stroke, Parkinson’s). Mitigations: start non-immersive, cap early sessions at 10 minutes, use teleport locomotion, avoid high-acceleration scenes, gradual acclimation ramp, confirm opt-out paths for medical populations.

Clinician training burden

The single biggest predictor of adoption failure. Clinicians unfamiliar with VR interfaces will not use the hardware. Fix: mandatory 1-day onboarding, peer champions per specialty, 30/60/90-day check-ins. Without it, utilization drops below 15% by month 3.

Skill-transfer and fidelity gaps

VR-learned skills don’t always transfer cleanly to OR or clinical setting. Mitigation: competency-based progression, in-simulation + in-context hybrid training, longitudinal follow-up assessments. Design for deliberate practice, not one-shot exposure.

Reimbursement uncertainty

Category III CPT codes have limited CMS rates. Commercial plan coverage varies. Prior authorization slows deployment. Fix: prioritize applications where reimbursement path is established (E1905 for CBT, RTM for XRHealth-style platforms) and pilot with payer-partners for novel categories.

Patient selection

VR is not universal. Cognitive impairment, severe psychiatric instability, baseline motion sensitivity, and some vestibular conditions are contraindications or require modified protocols. Build eligibility into the clinical workflow — don’t leave it to the VR rep.

Workflow integration

VR training added to an already-busy clinical schedule fails. Solution: embed into grand rounds, residency curricula, mandatory continuing education, or pre-op planning workflows. Proximie’s 2025–2026 direction on measuring OR workflow time is instructive: quantify the gain.

Hardware management

Expect 10–15% annual breakage or loss in clinical environments. Budget for it. Tethered straps, protective cases, printed protocols, and central MDM cut loss rates roughly in half.

Seven pitfalls we see on almost every AR/VR healthcare rollout

1. Jumping to full deployment without a pilot. Programs that deploy 40 headsets division-wide in month 1 almost always see <20% utilization by month 6. Pilot with 2–3 clinicians, measure, then scale.

2. Underbudgeting clinician training. Expensive hardware with $0 training = expensive paperweights. Budget minimum 10% of total program cost for training and ongoing support.

3. Assuming FDA clearance is optional. For therapeutic claims, it isn’t. Even for non-device education products, payer and enterprise conversations demand regulatory clarity. Map your pathway before prototyping.

4. Ignoring EHR / PACS / DICOM integration. If clinical data can’t flow between VR platform and patient record, clinicians stop using it. Budget integration work up front.

5. Picking the premium headset when the mid-range works. Apple Vision Pro is the right call for shoulder arthroscopy planning. It’s the wrong call for 40-resident surgical training. Match optics to use case.

6. Treating VR as a standalone intervention, not a care pathway component. The strongest deployments embed VR inside existing workflows — preoperative planning sessions, post-op rehabilitation programs, chronic pain management cycles. VR alone underperforms VR-plus-standard-care.

7. Underestimating compliance scope. HIPAA, IEC 62304, SBOM disclosure, BAAs, SOC 2. Compliance is a gate, not a feature. Start early, not when the first enterprise deal stalls.

A 6-question decision framework for AR/VR in healthcare

Q1. What’s the clinical problem, and is there RCT-grade evidence? Strong RCT evidence + FDA clearance: proceed. Pilot-only evidence: budget for your own validation study. No evidence: not yet.

Q2. Does an FDA-cleared device serve the application? Yes: evaluate vendor + reimbursement path. No: understand whether you’re building a device (FDA track) or a non-device education tool.

Q3. What’s the patient or trainee volume? <100/yr: probably skip or pilot with low-cost WebXR. 100–500/yr: off-the-shelf platform. 500+/yr: custom build starts to amortize.

Q4. What’s the reimbursement or outcomes pathway? E1905, RTM codes, workers’ comp, DME: clearer path. Self-pay or institutional absorption only: harder case.

Q5. What’s your clinician training + workflow integration readiness? Enthusiastic champion + EHR integration capacity: deploy. Un-trained + manual integration: fix workflow first.

Q6. What’s your compliance scope? HIPAA-only: most SaaS platforms work. FDA-cleared device required: regulatory strategy from day one. On-prem / private-cloud mandated: custom build likely.

A realistic 90-day AR/VR clinical rollout

What good looks like in each 30-day window:

Days 1–30: clinical pilot with one champion + one vendor

Buy 2–4 headsets + one vendor subscription. Run a 2-hour clinician onboarding. Pilot 1 clinical workflow with 10–20 patients or 5 trainees. Instrument everything: session duration, completion, patient-reported outcomes, clinician friction notes.

Days 31–60: expand to a specialty or service line

Add 4–8 more headsets. Bring in 4–6 more clinicians. Run a formal onboarding day. Start weekly utilization and outcome reporting to the service-line director. Align billing / coding workflows with payer coverage for reimbursable applications.

Days 61–90: full deployment + outcome measurement

Deploy the planned cohort. Run formal pre/post assessments on a defined patient or trainee subset. Present a 90-day retrospective with hard data to clinical leadership: continue, expand, or redirect. Document the clinical, financial, and operational learnings for a formal program plan.

EHR, PACS, and DICOM integration — where most deployments stall

The most common failure mode in clinical AR/VR: the pilot works, clinicians love it, but the data never reaches Epic, Cerner, or Allscripts. Administration stops championing, and utilization dies.

FHIR + HL7 + SMART on FHIR

The modern standard. FDA-cleared digital therapeutics and enterprise platforms increasingly ship FHIR-compatible APIs. Verify before procurement.

PACS + DICOM for imaging-based workflows

Preoperative planning (ImmersiveTouch, Surgical Theater) and intraoperative AR (AugMedics) require clean DICOM pipelines. Your enterprise imaging team owns this. Budget their time explicitly.

Outcome analytics and clinical registries

For therapy programs, outcome reporting into clinical registries (NSQIP, MIPS, ICHOM) matters for value-based care contracting. Most vendors export CSV; a few offer direct registry integration. Budget custom data pipeline work if registry integration is critical.

What’s actually changing in AR/VR healthcare in 2026

AI-generated patient anatomy is the biggest shift. Automated CT/MRI segmentation producing 3D models in under an hour. Surgical planning that took 4–8 hours of radiology tech work now takes minutes. Cost compression of 40–70% on planning workflows.

Apple Vision Pro is entering the OR via pilots. Shoulder arthroscopy case reports in 2025, neuronavigation prototyping in 2026. Not mainstream yet — cognitive load concerns in time-sensitive procedures — but the optics are compelling for non-time-critical applications.

Digital therapeutic CPT codes multiplying. E1905 set the precedent. Rejoyn (MDD) and DaylightRx (GAD) FDA approvals create momentum for additional codes. Expect 2–3 new CPT codes for behavioral health VR between 2026 and 2028.

5G-enabled surgical telepresence scaling. Proximie’s 2026 vision: intelligent OR co-pilot augmenting surgeons. 5G low-latency (<20ms) makes remote expert guidance viable at scale. Pilots active; broader deployment 2027+.

Robotic surgery + digital twins. Virtual Incision + NVIDIA Isaac for Healthcare (2025 announcement). Physiologically-realistic robotic-surgery simulation with AI-augmented scenarios. Training and pre-op rehearsal at scale.

Outcomes-based reimbursement contracting. Payers paying for efficacy, not VR hours. Emerging in mental health digital therapeutics. Will spread to pain management and rehab.

Premium-tier optics normalization. Vision Pro + Varjo XR-4 + Magic Leap 2 all driving enterprise adoption. Our Vision Pro business case playbook goes deep on when $3,499/unit is defensible.

When you should NOT deploy AR/VR (at least not yet)

Three honest cases:

Your clinical volume is under 100 patients or 10 trainees per year. Fixed costs don’t amortize. Pilot with low-cost WebXR or wait for vendor economics to improve.

Your clinicians are skeptical, untrained, and unsupported. Invest in onboarding, peer champions, and workflow integration first. Clinician-driven adoption is 10× more successful than administration-led.

Your compliance stack isn’t ready. HIPAA BAAs, SOC 2, IEC 62304, SBOM disclosure. If your clinical IT security team can’t approve a new SaaS vendor in under 90 days, fix that process first.

FAQ

What to Read Next

Ready to put AR/VR to work in your clinical program?

AR/VR in healthcare has crossed the line from interesting technology to measurable line item on a clinical budget. FDA clearances are stacking. Reimbursement codes are real. RCT evidence is solid across pain, rehab, behavioral, surgical, and diagnostic applications. The questions now are which clinical application, which vendor, which hardware, and when to build custom.

We’ve shipped real-time video, AI, and immersive healthcare software since 2005. If you’re scoping a pilot, evaluating vendors, navigating FDA strategy, or looking at a custom build — we’ll help you think through the decision honestly.